Angeles Clinic and Research Institute

Recent papers from Angeles Clinic and Research Institute

1. Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trialsNature Medicine · 2026
2. Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory Melanoma or Other Solid Tumors With BRAF Fusions or CRAF/RAF1 Fusions or Amplification: Phase II FIRELIGHT-1 SubstudyJCO Precision Oncology · 2026
3. Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)Nature Medicine · 2026
4. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialThe Lancet · 2016
5. A Phase 1 First-Time-in-Human, Open-Label Study of Nelistotug Administered to Patients with Advanced Solid TumorsClinical Cancer Research · 2026
6. Safety and efficacy of intratumoral MEDI1191, an IL-12 mRNA lipid nanoparticle, plus intravenous durvalumab in patients with advanced solid tumors: a first-in-human studyClinical Cancer Research · 2026
7. Phase 1/2 study of INCAGN01876, an anti-GITR agonist monoclonal antibody, plus immunotherapy for advanced cancersThe Oncologist · 2026
8. Factor V Leiden in Head and Neck Reconstruction: Institutional Experience and ProtocolJournal of Craniofacial Surgery · 2026
9. Tryptophan degradation by intestinal Bacteroides induces anti-tumor immunity and limits melanoma growthCell Reports Medicine · 2026
10. Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignanciesENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2026
11. Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 StudyJournal of Clinical Oncology · 2026
12. Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancerAnnals of Oncology · 2026
13. SYNERGY: A phase 1b/2 study of nenocorilant, a selective glucocorticoid receptor antagonist, plus nivolumab in patients with advanced solid malignancies.Journal of Clinical Oncology · 2026
14. A phase 3, international, multicenter, randomized, controlled trial of selective index lymph node resection versus therapeutic lymph node dissection after neoadjuvant immunotherapy for stage IIIB-D melanoma (MSLT-3/S2601/EORTC2519).Journal of Clinical Oncology · 2026
15. A randomized, controlled, multicenter, phase 3 study of RP1 (vusolimogene oderparepvec) combined with nivolumab vs physician’s choice of therapy in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy (IGNYTE-3).Journal of Clinical Oncology · 2026
16. The TIME trial: Phase II randomized controlled trial of time-of-day–specified nivolumab and ipilimumab for advanced melanoma.Journal of Clinical Oncology · 2026
17. Atezolizumab (A) plus pertuzumab/trastuzumab/hyaluronidase (PHESGO) in patients (pts) with solid tumors with ERBB2 alterations (alt): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.Journal of Clinical Oncology · 2026
18. First data disclosure from the first-in-human phase 1/2 trial of SMP-3124LP, the first investigational pegylated liposome CHK1 inhibitor, in patients with selected advanced solid tumors.Journal of Clinical Oncology · 2026
19. Assessment of recurrence risk in stage IIB/C melanoma across time: Implications for stratification and surveillance.Journal of Clinical Oncology · 2026
20. OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy with regulatable membrane-bound IL15 (mbIL15) in patients with advanced melanoma that has progressed on/after immune checkpoint inhibitors (ICI): Phase 2 results.Journal of Clinical Oncology · 2026